HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary—An expanding public health burden

International Journal of Drug Policy

Volumn 41, Issue , 2017, Pages 1-7

  Tarján, Anna ^a,b   Dudás, Mária ^c   Wiessing, Lucas ^d   Horváth, Gergely ^a,b   Rusvai, Erzsébet ^c   Tresó, Bálint ^c   Csohán, Ágnes ^c  

^a Hungarian National Focal Point   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^d EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

Harm reduction; Hepatitis C; HIV; Injecting drug use; New psychoactive substances; Risk behaviours

Indexed keywords

PSYCHOTROPIC AGENT;

ADULT; ARTICLE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; HUNGARY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POPULATION SIZE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; SUBSTANCE ABUSE; COMPLICATION; DRIED BLOOD SPOT TESTING; HARM REDUCTION; HOMELESS PERSON; INTERVIEW; NEEDLE SHARING; PREVENTIVE HEALTH SERVICE; PRISONER; QUESTIONNAIRE; SEXUAL BEHAVIOR; STATISTICS AND NUMERICAL DATA; UNSAFE SEX;

DRIED BLOOD SPOT TESTING; HARM REDUCTION; HEPATITIS C; HOMELESS PERSONS; HUMANS; HUNGARY; INTERVIEWS AS TOPIC; NEEDLE SHARING; NEEDLE-EXCHANGE PROGRAMS; PREVALENCE; PRISONERS; PSYCHOTROPIC DRUGS; PUBLIC HEALTH; RISK-TAKING; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; SURVEYS AND QUESTIONNAIRES; UNSAFE SEX;

EID: 85003815104     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2016.11.006     Document Type: Article

References (60)

1. Botescu, A., Abagiu, A., Mardarescu, M., Ursan, M., HIV/AIDS among injecting drug users in Romania. Report of a recent outbreak and initial response policies., 2012, EMCDDA, Lisbon.
2. Bourne, A., Reid, D., Hickson, F., Torres-Rueda, S., Steinberg, P., Weatherburn, P., Chemsex and harm reduction need among gay men in South London. International Journal of Drug Policy 26:12 (2015), 1171–1176, 10.1016/j.drugpo.2015.07.013.
3. Bruggmann, P., Accessing Hepatitis C patients who are difficult to reach: It is time to overcome barriers. Journal of Viral Hepatitis 19:12 (2012), 829–835, 10.1111/jvh.12008.
4. Bruggmann, P., Grebely, J., Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 26:Suppl. 1 (2015), S22–S26, 10.1016/j.drugpo.2014.08.014.
5. Cox, J., Morissette, C., De, P., Tremblay, C., Allard, R., Graves, L.,.. Roy, E., Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users. Substance Use & Misuse 44:4 (2009), 548–568, 10.1080/10826080802544349.
6. Csak, R., Demetrovics, Z., Racz, J., Transition to injecting 3,4-methylene-dioxy-pyrovalerone (MDPV) among needle exchange program participants in Hungary. Journal of Psychopharmacology 27:6 (2013), 559–563, 10.1177/0269881113480987.
7. Degenhardt, L., Mathers, B., Vickerman, P., Rhodes, T., Latkin, C., Hickman, M., Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. Lancet 376:9737 (2010), 285–301, 10.1016/s0140-6736(10)60742-8.
8. EASL recommendations on treatment of Hepatitis C 2015. Journal of Hepatology 63:1 (2015), 199–236, 10.1016/j.jhep.2015.03.025.
9. ECDC, Hepatitis C surveillance in Europe—2013. 2015, ECDC, Stockholm.
10. ECDC, EMCDDA, Prevention and control of infectious diseases among people who inject drugs. 2011, ECDC, Stockholm.
11. EMCDDA, Hepatitis C and injecting drug use: Impact, costs and policy options. 2004, EMCDDA, Lisbon.
12. EMCDDA, Protocol for the implementation of the EMCDDA key indicator drug related infectious diseases (DRID), draft version 6 October 2006. 2006 Retrieved March 2016, from EMCDDA http://drogfokuszpont.hu/wp-content/uploads/drid_protocol_2006.pdf.
13. EMCDDA, Standard stable 9. 2013 Retrieved 13 December 2013, from EMCDDA http://www.emcdda.europa.eu/themes/key-indicators/drid.
14. EMCDDA, Drug-related infectious diseases in Europe: Update from the EMCDDA expert network. 2015, Publications office of the European Union, Luxembourg.
15. EMCDDA, Injection of synthetic cathinones. Perspectives on drugs, 2015, EMCDDA, Lisbon.
16. EMCDDA, ECDC, Joint EMCDDA and ECDC rapid risk assessment: HIV in injecting drug users in the EU/EEA, following a reported increase of cases in Greece and Romania (Publication no. 10.2810/50417)., 2012 Retrieved 13 December 2013, from EMCDDA http://www.emcdda.europa.eu/publications/joint-publications/hiv-in-injecting-drug-users-2011.
17. EMCDDA, Europol, New drugs in Europe, 2012. EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA., 2013, Publications Office of the European Union, Luxembourg.
18. Fotiou, A., Micha, K., Paraskevis, D., Terzidou, M., Malliori, M., Hatzakis, A., HIV outbreak among injecting drug users in Greece. An updated brief report for the EMCDDA on the recent outbreak of HIV infections among drug injectors in Greece., 2012 Retrieved from http://www.emcdda.europa.eu/publications/ad-hoc/2012/greece-hiv-update.
19. Friedman, S.R., Rossi, D., Braine, N., Theorizing Big Events as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. International Journal of Drug Policy 20:3 (2009), 283–291, 10.1016/j.drugpo.2008.10.006.
20. Gazdag, G., Horvath, G., Szabo, O., Ungvari, G.S., Barriers to antiviral treatment in hepatitis C infected intravenous drug users. Neuropsychopharmacologia Hungarica 12:4 (2010), 459–462.
21. Giese, C., Igoe, D., Gibbons, Z., Hurley, C., Stokes, S., McNamara, S.,.. Fitzgerald, M., Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. Euro Surveillance, 20(40), 2015, 10.2807/1560-7917.es.2015.20.40.30036.
22. Gyarmathy, V.A., Csak, R., Balint, K., Bene, E., Varga, A.E., Varga, M.,.. Racz, J., A needle in the haystack—The dire straits of needle exchange in Hungary. BMC Public Health, 16(1), 2016, 157, 10.1186/s12889-016-2842-2.
23. Gyarmathy, V.A., Neaigus, A., Mitchell, M.M., Ujhelyi, E., The association of syringe type and syringe cleaning with HCV infection among IDUs in Budapest, Hungary. Drug and Alcohol Dependence 100:3 (2009), 240–247, 10.1016/j.drugalcdep.2008.10.014.
24. Hellard, M., Sacks-Davis, R., Gold, J., Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases 49:4 (2009), 561–573, 10.1086/600304.
25. Hellard, M.E., Aitken, C.K., Hocking, J.S., Tattooing in prisons—Not such a pretty picture. American Journal of Infection Control 35:7 (2007), 477–480, 10.1016/j.ajic.2006.08.002.
26. HNFP, 2010 National Report to the EMCDDA., 2010 Retrieved 13 December 2013, from HNFP http://drogfokuszpont.hu/wp-content/uploads/nr_10_en.pdf.
27. Hope, V.D., Cullen, K.J., Smith, J., Jessop, L., Parry, J., Ncube, F., Is the recent emergence of mephedrone injecting in the United Kingdom associated with elevated risk behaviours and blood borne virus infection?. Euro Surveillance, 21(19), 2016, 10.2807/1560-7917.es.2016.21.19.30225.
28. Horváth, G., Nyírády, A., Péterfi, A., Tarján, A., Drugs (report)., 2015 Retrieved 28 October 2016, from HNFP http://drogfokuszpont.hu/wp-content/uploads/HU_National_Report_2015.pdf.
29. Horváth, G., Nyírády, A., Tarján, A., Varga, O., Drugs (report)., 2016 Retrieved 28 October 2016, from HNFP http://drogfokuszpont.hu/wp-content/uploads/HU_National_Report_2016.pdf.
30. Horváth, G., Tarján, A., Harms and harm reduction., 2015 Retrieved 22 April 2016, from HNFP http://drogfokuszpont.hu/wp-content/uploads/HU_National_Report_2015.pdf.
31. Kinner, S.A., Jenkinson, R., Gouillou, M., Milloy, M.J., High-risk drug-use practices among a large sample of Australian prisoners. Drug and Alcohol Dependence 126:1–2 (2012), 156–160, 10.1016/j.drugalcdep.2012.05.008.
32. Kral, A.H., Bluthenthal, R.N., Lorvick, J., Gee, L., Bacchetti, P., Edlin, B.R., Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: Risk-factor analysis. Lancet 357:9266 (2001), 1397–1401, 10.1016/s0140-6736(00)04562-1.
33. Kurelac, I., Papic, N., Sakoman, S., Orban, M., Dusek, D., Coric, M., Vince, A., Intravenous drug users can achieve a high sustained virological response rate: Experience from Croatian Reference Center for viral hepatitis. Hepatitis Monthly 11:12 (2011), 986–992.
34. Lazarus, J.V., Sperle, I., Maticic, M., Wiessing, L., A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region. BMC Infectious Diseases, 14(Suppl. 6), 2014, S16, 10.1186/1471-2334-14-s6-s16.
35. Martin, N.K., Vickerman, P., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M., Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology 54:6 (2011), 1137–1144, 10.1016/j.jhep.2010.08.029.
36. Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., Hickman, M., Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55:1 (2012), 49–57, 10.1002/hep.24656.
37. Mathers, B.M., Degenhardt, L., Ali, H., Wiessing, L., Hickman, M., Mattick, R.P.,.. Strathdee, S.A., HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 375:9719 (2010), 1014–1028, 10.1016/s0140-6736(10)60232-2.
38. Mounteney, J., Griffiths, P., Sedefov, R., Noor, A., Vicente, J., Simon, R., The drug situation in Europe: An overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction 111:1 (2016), 34–48, 10.1111/add.13056.
39. OEP, A Hepatitis C vírus okozta krónikus májgyulladás diagnosztikája és terápiájának finanszírozási protokollja. 2013 Retrieved 22 April 2016, from EMMI http://www.oep.hu/data/cms989746/0703_hcv_finansz_protokoll.pdf.
40. Persico, M., Coppola, N., Rosato, V., Abenavoli, L., Masarone, M., De Luna, A., HCV antiviral therapy in injection drug users: Difficult to treat or easy to cure?. Annals of Hepatology 14:3 (2015), 325–332.
41. Péterfi, A., Treatment (report)., 2015 Retrieved 22 April 2016, from HNFP http://drogfokuszpont.hu/wp-content/uploads/HU_National_Report_2015.pdf.
42. Peterfi, A., Tarjan, A., Horvath, G.C., Csesztregi, T., Nyirady, A., Changes in patterns of injecting drug use in Hungary: A shift to synthetic cathinones. Drug Testing and Analysis 6:7–8 (2014), 825–831, 10.1002/dta.1625.
43. Racz, J., Csak, R., Farago, R., Vadasz, V., The phenomenon of drug change in the interviews with injecting drug users. Psychiatria Hungarica 27:1 (2012), 29–47.
44. Racz, J., Csak, R., Toth, K.T., Toth, E., Rozman, K., Gyarmathy, V.A., Veni, vidi, vici: The appearance and dominance of new psychoactive substances among new participants at the largest needle exchange program in Hungary between 2006 and 2014. Drug and Alcohol Dependence 158 (2016), 154–158, 10.1016/j.drugalcdep.2015.10.034.
45. Racz, J., Gyarmathy, V.A., Csak, R., New cases of HIV among people who inject drugs in Hungary: False alarm or early warning?. International Journal of Drug Policy 27 (2016), 13–16, 10.1016/j.drugpo.2015.05.026.
46. Rhodes, T., Risk environments and drug harms: A social science for harm reduction approach. International Journal of Drug Policy 20:3 (2009), 193–201, 10.1016/j.drugpo.2008.10.003.
47. Sypsa, V., Paraskevis, D., Malliori, M., Nikolopoulos, G.K., Panopoulos, A., Kantzanou, M.,.. Hatzakis, A., Homelessness and other risk factors for HIV infection in the current outbreak among injection drug users in Athens, Greece. American Journal of Public Health 105:1 (2015), 196–204, 10.2105/ajph.2013.301656.
48. Tarjan, A., Dudas, M., Gyarmathy, V.A., Rusvai, E., Treso, B., Csohan, A., Emerging risks due to new injecting patterns in hungary during austerity times. Substance Use & Misuse 50:7 (2015), 848–858, 10.3109/10826084.2015.978672.
49. Treso, B., Barcsay, E., Tarjan, A., Horvath, G., Dencs, A., Hettmann, A.,.. Takacs, M., Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary. Journal of Urban Health 89:1 (2012), 108–116, 10.1007/s11524-011-9626-x.
50. Turner, K.M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N.,.. Hickman, M., The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: Pooling of UK evidence. Addiction 106:11 (2011), 1978–1988, 10.1111/j.1360-0443.2011.03515.x.
51. UNODC, World drug report 2013., 2013, EMCDDA, Vienna.
52. UNODC, Injecting use of synthetic drugs. 2016 Retrieved 22 April 2016, from UNODC http://www.unodc.org/documents/scientific/Global_SMART_Update_Vol.15_web.pdf.
53. Van Hout, M.C., Bingham, T., A costly turn on: Patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. International Journal of Drug Policy 23:3 (2012), 188–197, 10.1016/j.drugpo.2012.01.008.
54. Vickerman, P., Hickman, M., May, M., Kretzschmar, M., Wiessing, L., Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction 105:2 (2010), 311–318, 10.1111/j.1360-0443.2009.02759.x.
55. Vickerman, P., Martin, N., Turner, K., Hickman, M., Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction 107:11 (2012), 1984–1995, 10.1111/j.1360-0443.2012.03932.x.
56. Vickerman, P., Martin, N.K., Roy, A., Beattie, T., Jarlais, D.D., Strathdee, S.,.. Hickman, M., Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. Drug and Alcohol Dependence 132:1–2 (2013), 172–181, 10.1016/j.drugalcdep.2013.01.020.
57. WHO, UNODC, UNAIDS, Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. 2012 revision ed., 2013, WHO, Geneva.
58. Wiessing, L., New EMCDDA toolkit for monitoring infectious diseases. 2014 Retrieved 28 April 2016, from EMCDDA http://www.emcdda.europa.eu/publications/drugnet/85.
59. Wiessing, L., Ferri, M., Grady, B., Kantzanou, M., Sperle, I., Cullen, K.J.,.. Mathei, C., Hepatitis C virus infection epidemiology among people who inject drugs in Europe: A systematic review of data for scaling up treatment and prevention. PLoS One, 9(7), 2014, e103345, 10.1371/journal.pone.0103345.
60. Wiessing, L., Likatavicius, G., Hedrich, D., Guarita, B., van de Laar, M.J., Vicente, J., Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveillance, 16(48), 2011.